Validity and reliability of the Brazilian version of the International Consultation on Incontinence Questionnaire Male Sexual Matters Associated with Lower Urinary Tract Symptoms Module.
André Carlos Santos Ferreira, Dayane Abreu Ribeiro, José Wicto Pereira Borges and 3 others
PMID 40332197WHAT IT FOUND
The Brazilian Portuguese questionnaire for men with lower urinary tract symptoms showed consistent scores.
It tracked urinary symptom severity and sexual satisfaction while asking about erections, ejaculation, pain during ejaculation and sex life.
Key findings
01The four questions behaved as one measure of sexual function problems, and they explained 78% of the score variation.
02The questionnaire’s total score was moderately linked to urinary symptom severity (r=0.67) and strongly linked to lower sexual satisfaction (r=-0.84).
03The items gave consistent scores, with both reliability measures at 0.95.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
It was done in one urology outpatient clinic at an oncology hospital, and most participants had cancer, so it may not apply to men with lower urinary tract symptoms in other settings. The study did not test whether using the questionnaire improves care or outcomes. The original validation used uroflowmetry and frequency-volume diary data, but these were not available, so the Brazilian version could not be compared directly with the original study. The paper reports 138 recruited men but does not give a separate analysed number or dropout count.
Declared interests
The study was funded by Brazilian research agencies CAPES, CNPq and FAPEMIG. No commercial sponsor or author conflict of interest is stated.
The easy way to misread this
Do not read this as evidence that the questionnaire improves patient care or that it works for all men with lower urinary tract symptoms. It was validated in one urology clinic in Brazil, and most participants had cancer.